Skip to content

CLEO Diagnostics Lists on the ASX to Advance its Simple Blood Test for the Accurate and Early Diagnosis of Ovarian Cancer

CLEO Diagnostics Ltd 2 mins read

Cleo Diagnostics (ASX:COV) lists on the ASX today aiming to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer, based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but not in non-malignant disease.  The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide. 

The platform is backed by over 10 years of scientific Research & Development at the Hudson Institute of Medical Research, with two clinical studies conducted with over 500 patients.  Pursuant to a licence agreement with the Hudson Institute of Medical Research, Cleo has a worldwide exclusive licence to commercialise the intellectual property which underpins its operations and the ovarian cancer tests.

There is no accurate and reliable detection test for ovarian cancer — a pap test does not detect ovarian cancer.  Ovarian cancer is the most lethal of all cancers affecting women in Australia, and a silent killer.  The current five year survival rate is 49% and this has not changed substantively in 50 years.

Ovarian cancers are often indistinguishable from common, non-cancerous disease.  Currently patients undergo a combined CA-125 blood test and ultrasound to provide an assessment of disease.  However, neither is sufficient for an accurate diagnosis and they are only used for surgical referral.  Invasive surgery to remove the ovaries remains the only way to definitively diagnose the presence of malignant disease.

Initial clinical use will focus on the surgical triage market to improve treatment outcomes for patients with ovarian cancer, and simultaneously avoid unnecessary surgery and anxiety for women with far more common non-cancerous conditions.  Beyond surgical triage, Cleo Diagnostics will conduct further clinical trials to evaluate the effectiveness of the underlying core technology for disease recurrence following surgery and ultimately aims to develop broader screening applications in the general population.

The CLEO surgical Triage Test is being developed as an easy to administer blood test that accurately distinguishes benign from malignant disease without surgical intervention. The potential benefits are significant:

  • Improved early evaluation of patients using a simple blood test, that provides an actual cancer diagnostic assessment before surgery is considered;
  • High specificity and sensitivity to identify cancer, allowing efficient referral of patients to an appropriate gynecological oncology surgeon for treatment;
  • Patients that are diagnosed with non-cancerous growths will benefit from more conservative management strategies; and
  • Substantial reduction in stress and anxiety experienced by women who undergo a ‘cancer scare’ and must wait for a surgical diagnosis.


Pending regulatory approval, the CLEO Triage Test also has the potential to provide significant benefits to the broader community, including:

  • Cost savings in the health care system (government, hospital, health insurance);
  • Improved care for women with non-cancerous tumours;
  • More efficient allocation of priority surgical beds; and
  • Community benefits associated with reduced hospital stays.


The clinical unmet worldwide need is urgent.  An accurate and early detection blood test could shift survivability for ovarian cancer significantly as seen with other cancers.  Cleo is advancing the availability of its simple blood test, under a modular execution strategy which is designed to eventually address all ovarian cancer detection markets with specific tests including surgical triage, recurrence, high risk, and early-stage screening.


Contact details:

Elvis Jurcevic
Investor Relations
+614 08 268 271


More from this category

  • Biotechnology
  • 01/12/2023
  • 23:07
HanchorBio Inc.

HanchorBio to Present at the ESMO Immuno-Oncology 2023 Annual Congress

SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023. Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.Title:…

  • Biotechnology, Medical Health Aged Care
  • 24/11/2023
  • 13:15
Island Pharmaceuticals

Island Pharmaceuticals doses first cohort in ISLA-101 Single Ascending Dose study

TheSingleAscendingDosestudyisadoseescalationstudy,inwhichthreecohorts ofhealthysubjectswillreceive escalatingdosesofISLA-101 Studywillensurethatadministereddosescansafelyachievebloodconcentrations of ISLA-101 that are predicted to be effective against the dengue virus Datareadoutfromthestudyisexpectedinearly2024 MELBOURNE Australia, 24 November 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to announce that it has dosed the first cohort in its Single Ascending Dose (SAD) study for ISLA-101,awell-knowndrugcandidatebeingrepurposedforthepreventionandtreatment of dengue and other mosquito (or vector) borne diseases. The Single Ascending Dose study is being run at Scientia Clinical Research’s clinical trial facilities in Sydney (NSW), Australia, by Contract Research Organisation, Beyond Drug Development (ASX: 25 September 2023). Studyresultsareexpectedinearly2024.Theinsightsgainedfromthisstudywillpavethe wayforoptimisingprotocolsforIsland’s plannedPhase2aPEACHclinicaltrial. CEO of Island…

  • Contains:
  • Biotechnology, Business Company News
  • 23/11/2023
  • 09:34

ASX Hopeful Aegros Appoints Ex-MP As Advisory Committee Chair

Australia’s leading blood fractionator announces a trio of strategic advisor appointments as it lays the groundwork for an IPO Aegros has established a Strategic Advisory Committee (SAC), to provide advice to the Board in preparation for the company’s Initial Public Offering (IPO). The high-profile SAC members will be drawn from experts in their fields, to provide the Board with strategic advice in the lead up to its IPO. This comes after the company signed an agreement with the Queensland Government to build a 1,000,000 litre facility in Springfield, southwest of Brisbane worth over $350 million. 23 November: AEGROS today cemented…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.